E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prophylaxis of A/H1N1sw influenza |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10022001 |
E.1.2 | Term | Influenza (epidemic) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To explore the antibody and cell mediated immune (CMI) responses to one 0.50 mL IM injection of egg-derived Focetria pandemic influenza vaccine in terms of quality and quantity of the antigen-specific T- and B-cell response in healthy adults aged 18-60 years. |
|
E.2.2 | Secondary objectives of the trial |
To explore the antibody responses to one injection of egg-derived Focetria pandemic influenza vaccine according to CHMP criteria in healthy adults aged 18-60 years. Although this study is not designed nor powered to draw conclusions regarding safety and tolerability (which are being evaluated in other ongoing studies), these variables will also be monitored in subjects receiving one IM injection of egg-derived Focetria pandemic influenza vaccine. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Written informed consent obtained; 2. Males and females from 18 years to 60 years of age on the day of enrolment; 3. Subjects in good health as determined by the outcome of medical history, physical assessment and clinical judgment by the Investigator; 4. Subjects are able to comply with all study procedures and are available for all clinic visits scheduled in the study; 5. Willingness to allow for blood samples to be stored beyond the study period, for potential additional future testing to better characterize immune response. |
|
E.4 | Principal exclusion criteria |
1. Subjects who are not able to comprehend and to follow all required study procedures for the whole period of the study; 2. Subjects with history or any illness that, in the opinion of the Investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study; 3. Subjects with any serious chronic or progressive disease according to judgment of the Investigator (including, but not limited to malignant neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease); 4. History of any anaphylaxis, serious vaccine reactions, or hypersensitivity to influenza viral proteins, to any excipients, and to eggs (including ovalbumin), and chicken proteins; 5. Subjects who have had seasonal influenza vaccine or documented confirmed seasonal influenza disease within 2 weeks prior to Day 1; 6. Receipt of another investigational agent within 4 weeks prior to enrolment, or before completion of the safety follow-up period in this or in another study; subjects unwilling to refuse participation in another clinical study throughout the end of this study; 7. Subjects who received any other vaccines within 4 weeks prior to enrolment in this study or who are planning to receive any vaccine within 4 weeks from the study vaccines; the only exception being plain seasonal influenza vaccines which are allowed until 2 weeks before and over 2 weeks after the study vaccination; 8. Subjects who have received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 12 weeks or plan to receive these products during the full length of the study; 9. Subjects with axillary temperature ≥ 38C (≥ 100.4F) or oral temperature ≥ 38.5C (≥ 101.3F) within 3 days of intended study vaccination; 10. Known or suspected impairment/alteration of immune function, for example resulting from: a. receipt of immunosuppressive therapy such as systemic corticosteroids known to be associated with the suppression of hypothalamic-pituitary-adrenal (HPA) axis (10 mg/day of prednisone or its equivalent) or chronic use of inhaled high-potency corticosteroids (e.g. budesonide 800�g/day or fluticasone 750�g/day) within 60 days prior to Visit 1, b. cancer chemotherapy within 5 years, c. receipt of immunostimulants within 60 days prior to Visit 1, d. history of HIV infection or HIV-related disease; 11. History of progressive or severe neurological disorders (including Guillain-Barre` syndrome and convulsions, but excluding febrile convulsions); 12. History of or clinically suspected developmental delay; 13. Bleeding diathesis; 14. Surgery planned during the study period that in the Investigator s opinion would interfere with the study; 15. Female subjects who are pregnant or nursing (breastfeeding) mothers, or females of childbearing potential who are sexually active and have not used any of the acceptable contraceptive methods for the 2 months before entering the study or do not plan to use them up to the end of the study; 16. Members of the research staff who have direct access to any study documents containing subject information. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
CMI endpoints will reflect frequencies and fold increases of antigen-specific CD4+ T cells (as determined by ICS/FACS analysis) and B lymphocytes (as determined by ELISpot or LDA-ELISA assay) eventually differentiated by their functional profile, at the relevant time points. Antibody responses to H1N1sw will be assessed on plasma samples obtained at days 1, 8, 22, and 202, by Hemagglutination Inhibition (HI) test, single radial haemolysis (SRH) and by microneutralization (MN). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 9 |